|
Friday 1st February 2002 |
Text too small? |
Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.
"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.
CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.
No comments yet
BPG - Amended FY26 Annual Report and Presentation
WIN - Winton - Chris Meehan resigns as Directo
TEM - Transaction in Own Shares
WCO - Share Purchase Plan
SKT - Sky ASM and Closing Date for Director Nominations
September 11th Morning Report
MEL - Dividend reinvestment plan strike price
MKR - High Grade Gold Drill Intersections from Pipeline Ridge
KMD - ASM Date and Closing Date for Director Nominations
PCT - Sale of PwC Tower now unconditional